HOME Research Insight Key Players in the Cell-based Assays Market Focus on Product Launches, Expansions, Acquisitions & Partnerships

Key Players in the Cell-based Assays Market Focus on Product Launches, Expansions, Acquisitions & Partnerships

The cell-based assays market is expected to reach USD 19.92 Billion by 2022 from USD 13.34 Billion in 2017, at a CAGR of 8.4%. Rising R&D investment, increase in the prevalence of chronic diseases, and the advantages of cell-based assays over traditional technologies are driving the growth of this market.

The cell-based assays market is consolidated in nature due to the presence of a large number of players. The key players in the market include KGaA (Germany), Becton, Dickinson and Company (U.S.), PerkinElmer Inc. (U.S.), Promega Corporation (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K), Thermo Fisher Scientific Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), BioTek Instruments, Inc. (U.S.), Lonza Group (U.S.), ProQinase GmbH (Germany), Charles River Laboratories, Inc (U.S.), Cisbio Bioassays (France), Miltenyi Biotec (Germany), Cell Biolabs, Inc. (U.S.), DiscoverX Corporation (U.S.), Marin Biologic Laboratories (U.S.), Biospherix, Ltd (U.S.), Essen BioScience Inc. (U.S.), Life Technologies Corporation (U.S.), BioAgilytix Labs. (U.S.), Enzo Life Sciences, Inc. (Switzerland), Aurelia Bioscience Ltd. (U.K. ), Selexis SA (U.S.), and QGel SA (Switzerland).

The key strategy followed by most companies in the cell-based assays market are product launches. This strategy accounted for the largest share of the overall growth strategies mapped from 2015 to 2017. Some of the leading players that adopted this strategy include Becton, Dickinson and Company (U.S.), Thermo Fischer Scientific Inc. (U.S.), Danaher Corporation (U.S.), and Cell Signaling Technology, Inc. (U.S.).

Thermo Fischer Scientific Inc. (U.S.) dominated the cell-based assays market in 2017. The company provides cell-based assays through its Life Sciences Solutions and Analytical Instruments, business division. Thermo Fischer Scientific Inc. derives a majority of its revenue from the North American cell-based assays market. The company focuses on providing sophisticated products like reagents, assay kits and instruments. It also focuses on improving its market presence via expansions and collaborations.

Becton, Dickinson and Company (U.S.) commanded the second-largest share of the global cell-based assays market in 2016. This company operates through two business segments, namely, BD Medical and BD Life Sciences. The company has a strong geographic presence with manufacturing sites in 25 countries. The efficient sales network in the U.S. and European regions as well as in the rapidly growing Asian region has supported the company’s position in the global cell-based assays market. The company has mainly focused on organic growth strategies, primarily product launches.

Related Reports:

Cell Based Assays Market, By Product (Reagents, Assay Kits, Microplates, Cell Lines, Service), Application (Research, Drug Discovery, ADME Studies, Toxicology), End User (Biopharmaceutical Companies, Academic Institutions, CRO) – Global Forecast to 2022

Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support

US : 1-888-600-6441

Search reports